Back to today’s briefing

Story perspectives

FDA Approves Breakthrough Blood Tests for Alzheimer's Detection

5/25/2025

41 8

Summary

Story summary

The FDA has greenlit the Lumipulse blood test from Fujirebio, revolutionizing Alzheimer’s diagnosis by identifying amyloid plaques with minimal invasiveness and lower costs compared to traditional PET scans and spinal taps. Meanwhile, USC researchers have unveiled the 5ADCSI test, which assesses five biomarkers for early detection, making Alzheimer’s screening more accessible for patients.

1 of 1

Story summary

The FDA has greenlit the Lumipulse blood test from Fujirebio, revolutionizing Alzheimer’s diagnosis by identifying amyloid plaques with minimal invasiveness and lower costs compared to traditional PET scans and spinal taps. Meanwhile, USC researchers have unveiled the 5ADCSI test, which assesses five biomarkers for early detection, making Alzheimer’s screening more accessible for patients.